Menarini Asia-Pacific, a member of the world's largest Italian biopharmaceutical company, officially inaugurated the establishment of Menarini (China) Investment Co. Ltd. and the opening of its national headquarters on 29 October 2013 at the Wuhan National Bioindustry Base ("Wuhan Biolake") in Hubei Province, China.
Menarini Biomarkers Singapore (MBS) is a company fully owned by Menarini Group.
MBS mission is to discover predictive immunorelated biomarkers on single cells in order to develop DEPArray applications for Precision Medicine providing firm diagnosis and prognosis in the earliest stages of a disease and/or to optimize treatments for individual patients. In addition, MBS aims to identify markers on circulating fetal cells to develop DEPArray applications and isolate these cells from liquid biopsies for genetic screening.
MBS is working in two directions:
- Single cells from pathological tissues as a source of new biomarkers
- Single cells from liquid biopsies (circulating rare cells as biosensors)
The ability to identify predictive immune-related biomarkers for stratifying and subgrouping patients represent the next step forward in improving the quality of clinical care and meet Precision Medicine expectations.
Menarini Biomarkers Singapore operates through research collaboration partnership with public research institutions (PRIs) providing technologies, personnel and funding in order to achieve the milestones and deliverables defined in specific project plans.
In 2016, MBS has formalized two (2) project agreements under the framework of Master Research Collaboration Agreements (RCA) with SingHealth and one (1) RCA agreement with Singapore Eye Research Institute (SERI).
The RCA partnership between MBS and PRIs will allow clinicians and scientists from both parties to collaborate together so as to identify and develop important diagnostic and prognostic biomarkers for precision or personalized medicine.